CE Mark approval wins by ExThera for Seraph 100

Seraph 100 by ExThera Medical, developed for pathogen reduction during bloodstream infection gets the CE Mark approval. Obtaining the CE mark approval confirms the safety of Seraph 100.

 It imparts innovative therapy for efficient and fast treatment of infections. It imparts an effective alternative for bloodstream infection treatment. Seraph 100 acts as a sorbent-type blood filter. It can rapidly minimize the concentration of virus, bacteria and fungi in entire blood.

The therapeutic utilization of Seraph 100 was evaluated to treat patients who have drug-resistant and drug-susceptible bloodstream infections. Seraph 100 showed significant reduction in the pathogen concentration in both cases.